EGFR and non-small cell lung carcinoma: It has been demonstrated that the majority of oncogenic drivers, including EGFR and KRAS, activate the PI3K/AKT/mTOR pathway, which is essential for tumorigenesis and metastasis in NSCLC [16,17,18].